Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred


IMPACT FACTOR 2018: 3.014
5-year IMPACT FACTOR: 3.162

CiteScore 2018: 3.09

SCImago Journal Rank (SJR) 2018: 1.482
Source Normalized Impact per Paper (SNIP) 2018: 0.820

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 384, Issue 3

Issues

Calpastatin Exon 1B-Derived Peptide, a Selective Inhibitor of Calpain: Enhancing Cell Permeability by Conjugation with Penetratin

S. Gil-Parrado / I. Assfalg-Machleidt / F. Fiorino / D. Deluca / D. Pfeiler / N. Schaschke / L. Moroder / W. Machleidt
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/BC.2003.045

Abstract

The ubiquitous calpains, u- and m-calpain, have been implicated in essential physiological processes and various pathologies. Cell-permeable specific inhibitors are important tools to elucidate the roles of calpains in cultivated cells and animal models. The synthetic Nacetylated 27-mer peptide derived from exon B of the inhibitory domain 1 of human calpastatin (CP1B) is unique as a potent and highly selective reversible calpain inhibitor, but is poorly cell-permeant. By addition of N-terminal cysteine residues we have generated a disulfide-conjugated CP1B with the cell-penetrating 16-mer peptide penetratin derived from the third helix of the Antennapedia homeodomain protein. The inhibitory potency and selectivity of CP1B for calpain versus cathepsin B and L, caspase 3 and the proteasome was not affected by the conjugation with penetratin. The conjugate was shown to efficiently penetrate into living LCLC 103H cells, since it prevents ionomycin-induced calpain activation at 200-fold lower concentration than the non-conjugated inhibitor and is able to reduce calpain triggered apoptosis of these cells. Penetratin-conjugated CP1B seems to be a promising alternative to the widely used cell-permeable peptide aldehydes (e.g. calpain inhibitor I) which inhibit the lysosomal cathepsins and partially the proteasome as well or even better than the calpains.

About the article

Published Online: 2005-06-01

Published in Print: 2003-03-14


Citation Information: Biological Chemistry, Volume 384, Issue 3, Pages 395–402, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2003.045.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Vera Gonscherowski, Bernhard F. Becker, Louis Moroder, Elena Motrescu, Shirley Gil-Parrado, Torsten Gloe, Matthias Keller, and Stefan Zahler
American Journal of Physiology-Heart and Circulatory Physiology, 2006, Volume 290, Number 5, Page H2035
[2]
Marc Bartoli, Nathalie Bourg, Daniel Stockholm, Fabrice Raynaud, Antony Delevacque, Yang Han, Perrine Borel, Kenza Seddik, Nasser Armande, and Isabelle Richard
Journal of Biological Chemistry, 2006, Volume 281, Number 51, Page 39672
[3]
Michele Curcio, Ivan L. Salazar, Miranda Mele, Lorella M.T. Canzoniero, and Carlos B. Duarte
Progress in Neurobiology, 2016, Volume 143, Page 1
[4]
Marton Siklos, Manel BenAissa, and Gregory R.J. Thatcher
Acta Pharmaceutica Sinica B, 2015, Volume 5, Number 6, Page 506
[5]
Hyunil Jo, Nataline Meinhardt, Yibing Wu, Swapnil Kulkarni, Xiaozhen Hu, Kristin E. Low, Peter L. Davies, William F. DeGrado, and Doron C. Greenbaum
Journal of the American Chemical Society, 2012, Volume 134, Number 42, Page 17704
[6]
Alicja Bukowska, Uwe Lendeckel, Stefanie M. Bode-Böger, and Andreas Goette
Cardiovascular Therapeutics, 2012, Volume 30, Number 3, Page e115
[7]
John Anagli, Yuxia Han, Laura Stewart, Dongmei Yang, Ashkhen Movsisyan, Kadija Abounit, and Donald Seyfried
Biochemical and Biophysical Research Communications, 2009, Volume 385, Number 1, Page 94
[8]
Serge Auvin, Bernadette Pignol, Edith Navet, Morgane Troadec, Denis Carré, José Camara, Dennis Bigg, and Pierre-E. Chabrier
Bioorganic & Medicinal Chemistry Letters, 2006, Volume 16, Number 6, Page 1586
[9]
Andrew D. Abell, Karina M. Brown, James M. Coxon, Matthew A. Jones, Sigeru Miyamoto, Axel T. Neffe, Janna M. Nikkel, and Blair G. Stuart
Peptides, 2005, Volume 26, Number 2, Page 251
[10]
Gunnar P.H. Dietz and Mathias Bähr
Molecular and Cellular Neuroscience, 2004, Volume 27, Number 2, Page 85
[11]
Tomoko Sengoku, Vimala Bondada, Duane Hassane, Sam Dubal, and James W. Geddes
Experimental Neurology, 2004, Volume 188, Number 1, Page 161
[12]
Isaac O Donkor
Expert Opinion on Therapeutic Patents, 2011, Volume 21, Number 5, Page 601
[13]
O. Popp, M. Heidinger, L. Ruiz-Heinrich, C. Ries, M. Jochum, and S. Gil-Parrado
Biological Chemistry, 2003, Volume 384, Number 6
[14]
José Pfizer, Irmgard Assfalg-Machleidt, Werner Machleidt, and Norbert Schaschke
Biological Chemistry, 2008, Volume 389, Number 1
[15]
R. Chandramohanadas, P. H. Davis, D. P. Beiting, M. B. Harbut, C. Darling, G. Velmourougane, M. Y. Lee, P. A. Greer, D. S. Roos, and D. C. Greenbaum
Science, 2009, Volume 324, Number 5928, Page 794
[16]
Christiane Volbracht, Boon Tin Chua, Chee Peng Ng, Ben A. Bahr, Wanjin Hong, and Peng Li
Journal of Neurochemistry, 2005, Volume 93, Number 5, Page 1280
[17]
A Rudy, N López-Antón, N Barth, G R Pettit, V M Dirsch, K Schulze-Osthoff, M Rehm, J H M Prehn, M Vogler, S Fulda, and A M Vollmar
Cell Death and Differentiation, 2008, Volume 15, Number 12, Page 1930
[18]
Ferdinando Fiorino, Shirley Gil-Parrado, Irmgard Assfalg-Machleidt, Werner Machleidt, and Luis Moroder
Journal of Peptide Science, 2007, Volume 13, Number 1, Page 70
[19]
Tamás Letoha, Szilvia Gaál, Csaba Somlai, Zsolt Venkei, Hristos Glavinas, Erzsébet Kusz, Ernö Duda, András Czajlik, Ferenc Peták, and Botond Penke
Journal of Peptide Science, 2005, Volume 11, Number 12, Page 805

Comments (0)

Please log in or register to comment.
Log in